These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21311483)

  • 1. [Efficacy of pantogam in the treatment of hyperkinetic disorders in children].
    Sukhotina NK; Konovalova VV; Kryzhanovskaia IL; Kupriianova TA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):24-8. PubMed ID: 21311483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pantogam augmentation in hyperkinetic behavior disorder treatment].
    Kupriyanova TA; Koren EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):66-69. PubMed ID: 27456906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and tolerability of pantogam activ in patients with partial epilepsy].
    Poverennova IE; Iakunina AV; Kalinin VA; Savel'eva NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2):54-9. PubMed ID: 21350425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pantogam in daily psychiatric practice].
    Kontsevoĭ VA; Rotshteĭn VG; Bogdan MN; Riakhovskiĭ VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):34-9. PubMed ID: 18427457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pantogam activ (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension].
    Smulevich AB; Volel BA; Ternovaya ES; Nikitina YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):40-49. PubMed ID: 26978493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological effects and clinical application of pantogam and pantogam active].
    Voronina TA; Litvinova SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):132-139. PubMed ID: 28884730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pantogam in the treatment of patients with organic brain lesions of different genesis].
    Rogacheva TA; Mel'nikova TS; Krasnoslobodtseva LA; Nazmetdinova DM; Lapin IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(10):34-9. PubMed ID: 21183912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pantogam active in the complex treatment of dystonic hyperkineses].
    Katunina EA; Malykhina EA; Avanesova OV; Makarova AA; Abdurakhmanova EK; Gridiakin VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 2):57-61. PubMed ID: 21389940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of combat stress in the development of chronic pain syndrom in veterans and its treatment by pantogam active].
    Pal'tsev AI; Torgashov MN; Vorontsova IuS; Baiandina EV; Luniakina SB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(9):43-6. PubMed ID: 21246890
    [No Abstract]   [Full Text] [Related]  

  • 10. [Psychophysiological effects of combined administration of pantogam and potassium orotate in patients with neurotic disorders].
    Ben'kovich BI; Gorshkova IA; Gershanovich II; Faĭzulloev AZ
    Eksp Klin Farmakol; 2001; 64(3):26-8. PubMed ID: 11558433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacotherapy of psychomotor developmental delay in 6-12 months preterm infants with hypoxic-ischemic encephalopathy (the double-blind comparative multicenter placebo-controlled study)].
    Zavadenko NN; Guzeva VI; Gaynetdinova DD; Davydova LA; Zavadenko AN; Romanova TA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10):30-39. PubMed ID: 31793540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preventive and cessation therapy of mental disorders in patients with the acute coronary syndrome].
    Medvedev VE; Epifanov AV; Zverev KV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(4):42-8. PubMed ID: 22810740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of pantogam in patients with moderate cognitive disorders of vascular genesis].
    Mikhaĭlova NA; Kamchatov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(12 Suppl 2):47-50. PubMed ID: 20879105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid].
    Zavadenko NN; Suvorinova NY; Vakula IN; Malinina EV; Kuzenkova LM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):39-45. PubMed ID: 28638029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam].
    Kupriyanova TA; Koren EV; Alabusheva NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11. Vyp. 2):75-79. PubMed ID: 29359723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of cognitive impairment in children and adolescents with cerebral palsy treated with pantocalcin].
    Batysheva TT; Platonova AN; Chebanenko NV; Bykova OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(9):48-53. PubMed ID: 24107880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia].
    Tiganov AS; Panteleeva GP; Abramova LI; Bologov PV; Kananovich PS; Omel'chenko MA; Nikiforova IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):72-80. PubMed ID: 28374697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and correction of cognitive impairment in preschool age children with epilepsy].
    Guzeva VI; Guzeva VV; Guzeva OV; Okhrim IV; Zgoda VN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):51-55. PubMed ID: 26525622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and neurophysiological objectification and evaluation of treatment efficacy in children with perinatal hypoxic-ischemic injury of the CNS].
    Grebennikova OV; Zavadenko AN; Rogatkin SO; Medvedev MI; Degtiareva MG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):63-7. PubMed ID: 24874320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of nootropic agents on visual functions and lacrimal antioxidative activity in patients with primary open-angle glaucoma].
    Davydova NG; Kuznetsova TP; Borisova SA; Abdulkadyrova MZh
    Vestn Oftalmol; 2006; 122(6):42-5. PubMed ID: 17217203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.